Kawasaki disease in newborns and infants: Refractory forms to immunoglobulin therapy;Maladie de Kawasaki chez le nourrisson et l'enfant: Formes réfractaires aux immunoglobulines

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 5, 2004, Pages 522-528

  Lucron, H ^a   Bosser, G ^a   Lethor, J P ^a   Sommelet, D ^a   Feillet, F ^a   Burger, G ^a   Monin, P ^a   Marcon F ^a  

^a HÔPITAL D ENFANTS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

ADOLESCENT; ANGIOCARDIOGRAPHY; ARTICLE; BODY WEIGHT; CHILD; CORONARY ARTERY ANEURYSM; FEMALE; FEVER; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HUMAN; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES;

EID: 2542477062     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Clinical observation of 50 patients. Jpn J Allergy 1967; 16: 178-222.
2. Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr 1975; 86: 892-8.
3. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki Syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7.
4. Newburger JW, Takahashi M, Beiser et al. Single infusion of intravenous gamma globulin compared to four daily doses in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-9.
5. Furusho K, Nakano H, Shinomiya K et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-8.
6. Terai M, Shulman ST. Prevalence of coronary abnormalities in Kawasaki disease is highly dependant on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888-93.
7. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-61.
8. Laupland KB, Dele Davis H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999; 20: 177-83.
9. Burns JC, Capparelli EV, Brown JA et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998; 17: 1144-8.
10. Fukunishi M, Kikkawa M, Hamana K et al. Prediction of non-responsiveness to intravenous high-dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000; 137: 172-6.
11. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000; 154: 694-9.
12. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24: 145-8.
13. Barron KS, Shulman ST, Rowley A et al. Report of the national institutes of health workshop on Kawasaki disease. J Rheumatol 1999; 26: 170-90.
14. Okada Y, Shinohara M, Kobayashi T et al. Effect of corticosteroids in addition to intravenous gammaglobulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003; 143: 363-7.
15. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000; 137: 723-6.
16. Shinohara M, Sone K, Tomomasa T, Mrikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999; 135: 465-9.
17. Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999; 135: 411-3.
18. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146-9.
19. Takagi N, Kihara M, Yamaguchi S et al. Plasma exchange in Kawasaki disease. Lancet 1995; 346: 1307.
20. Villain E, Kachaner J, Sidi D, Blaysat G, Piechaud JF, Pedroni E. Essai de prévention des anévrismes coronaires de la maladie de Kawasaki par échanges plasmatiques ou perfusion d'immunoglobulines. Arch Fr Pediatr 1987; 44: 79-83.
21. Tizard EJ, Suzuki A, Levin M, Dillon MJ. Clinical aspects of 100 patients with Kawasaki disease. Arch Dis Child 1991; 66: 185-8.
22. Gaudelus J, Guillois B, Paries J. Le syndrome de Kawasaki en France. Enquête rétrospective sur 5 ans. Med Mal Infect 1998; 28: 542-9.
23. Chantepie A, Mauran P, Lusson JR, Vaillant MC, Bazio A. Complications cardiovasculaires du syndrome de Kawasaki: résultats d'une enquête cardiopédiatrique multicentrique française. Arch Pediatr 2001; 8: 713-9.
24. Asai T. Evaluation method for the degree of seriousness in Kawasaki disease. Acta Paediatr Jpn 1983; 25: 170-5.
25. Newburger JW. Kawasaki disease: who is at risk? J Pediatr 2000; 137: 149-52.
26. De Zorzi A, Colan SD, Gauvreau K, Baker AI, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133: 254-8.
27. Tsuda E, Kamiya T, Kimura K, Ono Y, Echigo S. Coronary artery dilation exceeding 4 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening. Pediatr Cardiol 2002; 23: 9-14.
28. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000; 105: E78.
29. Guillevin L, Mahr A, Cohen P. Les vascularites nécrosantes systémiques: classification et stratégies actuelles de traitement. Rev Med Interne 2003; 24: 172-82.
30. Gorlin JB. Therapeutic plasma exchange and cytapheresis in pediatric patients. Transfus Sci 1999; 21: 21-39.